Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High Court Won’t Hear Covidien Patent Appeal

This article was originally published in The Gray Sheet

Executive Summary

The company had asked the Supreme Court to hear arguments to restore a $176 million patent infringement judgment against Ethicon. A lower court voided the award because Ethicon developed a prototype before Covidien’s patents were filed.

You may also be interested in...



Appeals Court Supports Patent Board Flexibility In Ethicon Case

Ethicon argued that a US Patent and Trademark Board policy allowing the same panel to decide whether to accept a patent challenge for review and issue a final ruling on its validity violates due process. A split Federal Circuit panel disagreed and supported the patent board’s finding that Ethicon’s surgical staple patent is invalid.

Court Grants Covidien Injunction Over Ethicon Endo-Surgery’s Surgical Shears

Covidien argues that despite a previous court ruling under appeal that Ethicon infringed on several of Covidien’s patents, the company has continued to use those designs in their line of Harmonic Ace surgical products.

Patent Reform A Reality: Costs And Opportunities Ahead

Comprehensive patent reform, which finally passed Congress last week after six years of debate, is likely to add new costs and uncertainties for device companies, but also important new opportunities for the most proactive of firms, patent attorneys say.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel